+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biosimilar Monoclonal Antibodies Market by Molecule Class, Indication, Dosage Form, Distribution Channel, End User - Global Forecast to 2030- Product Image
Biosimilar Monoclonal Antibodies Market by Molecule Class, Indication, Dosage Form, Distribution Channel, End User - Global Forecast to 2030- Product Image
Sale

Biosimilar Monoclonal Antibodies Market by Molecule Class, Indication, Dosage Form, Distribution Channel, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 197 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6010903
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Biosimilar Monoclonal Antibodies Market grew from USD 9.47 billion in 2024 to USD 11.73 billion in 2025. It is expected to continue growing at a CAGR of 23.26%, reaching USD 33.22 billion by 2030.

Demystifying the Rise of Biosimilar Monoclonal Antibodies

In recent years the biosimilar monoclonal antibody landscape has experienced a profound shift, emerging as a cornerstone of modern therapeutic strategy and cost management. These biologics, designed to match the safety, purity, and potency profiles of original reference products, are rapidly gaining traction as high-value alternatives across oncology, immunology, and hematology. The convergence of patent expirations on key molecule classes-spanning Anti CD20 and Anti HER2 antibodies to Anti Vascular Endothelial Growth Factor agents, colony stimulating factors, and TNF inhibitors-has unlocked a wave of biosimilar pipelines poised to challenge entrenched market leaders.

Advancements in cell line development, high-throughput analytical platforms, and scalable biomanufacturing techniques have been instrumental in compressing development timelines and fortifying product consistency. Payors and health systems are increasingly incentivizing biosimilar adoption to rein in escalating drug expenditures, while providers recognize the opportunity to broaden patient access to life-saving therapies. Nevertheless, navigating regulatory heterogeneity, ensuring immunogenicity comparability, and fostering clinician confidence remain critical priorities. As the sector matures, stakeholders must remain vigilant to evolving quality standards and harness collaborative frameworks to drive seamless market integration and sustainable growth.

Pioneering Forces Reshaping the Biosimilar mAb Market

Regulatory evolution has served as a primary catalyst for the biosimilar monoclonal antibody market’s rapid ascendancy. Streamlined pathways for analytical and clinical demonstration of similarity, coupled with clear guidance on interchangeability, foster a more predictable approval environment. This regulatory clarity has prompted developers to invest in continuous bioprocessing methods, single-use bioreactors, and digital twin technologies that enhance process reproducibility and minimize production risk.

Simultaneously, patent expiry waves across flagship biologics are creating unprecedented market access opportunities. Strategic alliances between innovator and biosimilar developers, alongside contract manufacturing partnerships, are accelerating scale-up and market entry. Artificial intelligence-driven cell culture optimization and real-world evidence generation further bolster confidence in biosimilar performance, offering health systems robust data to support formulary inclusion. These converging forces are reshaping competitive dynamics, compelling manufacturers to balance cost leadership with patient-centric innovation.

Assessing the Cumulative Impact of US Tariffs in 2025

The imposition of new tariff measures in 2025 has introduced complex challenges for biosimilar monoclonal antibody supply chains and pricing strategies. These tariffs, levied on components and excipients sourced internationally, have contributed to upward pressure on cost of goods and extended lead times for critical raw materials. Manufacturers are contending with fluctuating duties on cell culture media, single-use assemblies, and cold chain logistics, prompting a reassessment of global sourcing strategies.

In response, organizations are adopting diversified supplier networks, near-shoring key production steps, and negotiating long-term procurement agreements to insulate against tariff volatility. Concurrently, value-based contracting models and risk-sharing arrangements with payors are emerging as effective mechanisms to maintain competitive net pricing. By proactively addressing tariff impacts through operational resilience and innovative contracting, industry leaders can safeguard margins and ensure uninterrupted patient access.

In-Depth Segmentation Analysis Illuminates Market Dynamics

A granular segmentation of the biosimilar monoclonal antibody market reveals nuanced growth drivers across therapeutic classes, clinical indications, and delivery modalities. Molecule classes such as Anti CD20 and Anti HER2 antibodies continue to attract significant R&D investment, while Anti Vascular Endothelial Growth Factor agents-specifically Aflibercept, Bevacizumab, and Ranibizumab-are unlocking oncology and ophthalmology applications. Colony stimulating factors, including Filgrastim and Pegfilgrastim, sustain their role in supportive care, and TNF inhibitors like Adalimumab, Etanercept, and Infliximab remain central to autoimmune disease management.

Further differentiation emerges when considering clinical indications and dosage forms. Inflammatory bowel disease therapies distinguish between Crohn disease and ulcerative colitis, while oncology biosimilars address breast, colorectal, and lung cancer subtypes. Psoriasis agents span plaque psoriasis and psoriatic arthritis, and rheumatoid arthritis biosimilars cover both adult and juvenile idiopathic populations. The array of administration formats-from liquid solutions to prefilled pens, syringes, and both liquid vials and lyophilized powder vials-allows manufacturers to align with provider and patient preferences. Distribution channels via traditional pharmacy networks and digital platforms intersect with diverse end-user environments, encompassing private and public hospital pharmacies, chain and independent retail pharmacies, and specialized dermatology, oncology, and rheumatology clinics. This multidimensional view underscores the importance of targeted strategies that leverage specific segment dynamics to optimize market penetration.

Regional Variations Uncover Growth Frontiers

Regional insights into biosimilar monoclonal antibodies highlight distinct market landscapes shaped by regulatory frameworks, healthcare infrastructure, and reimbursement policies. In the Americas, robust payer consolidation and well-established substitution protocols have accelerated biosimilar volume uptake, especially in key therapeutic segments such as oncology and autoimmune diseases. Latin American markets, while demonstrating potential for rapid growth, often face hurdles related to budget constraints and complex import regulations.

In Europe, Middle East & Africa, harmonized approval pathways under centralized EMA guidelines coexist with divergent national pricing and tender mechanisms, leading to variable adoption rates. Nations with aggressive biosimilar incentive schemes and hospital tender programs have witnessed double-digit penetration, while emerging markets within the region continue to build capacity and clinician familiarity. Across Asia-Pacific, expansive patient populations and government initiatives to curb healthcare expenditure are driving biosimilar expansion. However, varying levels of regulatory maturity and local manufacturing capabilities influence commercialization timelines and market access strategies.

Strategic Movements Among Leading Biosimilar Innovators

Leading biosimilar developers are executing multifaceted strategies to secure competitive advantage and scale global footprint. Established generics and biosimilars pioneers have augmented their portfolios through strategic acquisitions and licensing agreements, integrating high-value monoclonal antibody candidates into their pipelines. Collaborations between biopharma innovators and contract development and manufacturing organizations are streamlining production scale-up, while targeted joint ventures in emerging markets facilitate regulatory navigation and local market entry.

Innovator companies are also adapting to competition by extending their own patent portfolios and offering authorized biosimilars to maintain market share. Upstream investments in advanced analytics, process intensification, and digital monitoring systems are enhancing supply chain visibility and ensuring consistent product quality. By leveraging these strategic initiatives, top players are not only defending existing market positions but also establishing differentiators in biosimilar efficacy, safety, and service offerings.

Actionable Strategies for Capturing Market Share in mAb Biosimilars

To capitalize on burgeoning opportunities in biosimilar monoclonal antibodies, industry leaders should prioritize an integrated approach encompassing regulatory engagement, technological innovation, and stakeholder collaboration. Early dialogue with health authorities to align on similarity protocols and interchangeability requirements can accelerate approval timelines and mitigate compliance risk. Concurrently, investment in process intensification technologies, such as perfusion bioreactors and continuous chromatography, will bolster manufacturing agility and cost efficiency.

Differentiated service models that encompass patient support programs, digital adherence tools, and physician education platforms can enhance market acceptance and reduce time to formulary inclusion. Expanding regional capabilities through strategic alliances and local production partnerships will further optimize supply chain resilience and market responsiveness. Lastly, embedding real-world evidence generation into launch planning will provide payors and providers with robust data to support therapeutic value propositions, paving the way for sustainable market share growth.

Robust Research Framework Underpinning Our Insights

Our research framework integrates comprehensive primary and secondary methodologies to deliver a robust understanding of the biosimilar monoclonal antibody landscape. Primary research draws on one-on-one interviews with C-suite executives, R&D leaders, regulatory specialists, and payor decision-makers, ensuring direct insights into strategic priorities and market access challenges. Secondary research encompasses peer-reviewed publications, regulatory filings, corporate financial disclosures, and commercial databases to validate emerging trends and benchmark performance metrics.

Data triangulation is applied to reconcile market intelligence with bottom-up and top-down sizing approaches, while a dedicated expert panel conducts rigorous quality assurance reviews at each stage. Geographic coverage spans North America, Europe, Middle East & Africa, and Asia-Pacific, enabling cross-regional comparisons and opportunity assessments. This disciplined methodology underpins our actionable findings and empowers stakeholders with the evidence base needed to drive strategic decision-making.

Conclusion Highlighting the Path Ahead for Biosimilar mAbs

The biosimilar monoclonal antibody market stands at a pivotal juncture, characterized by favorable patent dynamics, regulatory advances, and burgeoning demand for cost-effective therapies. As industry participants refine their manufacturing processes, forge strategic alliances, and harness digital innovations, the sector is poised for sustained growth and heightened competition.

Yet, success will hinge on the ability to navigate evolving tariff regimes, align with diverse regional requirements, and deliver compelling real-world evidence to support product differentiation. By embracing a holistic market strategy-one that integrates segmentation precision, regional adaptability, and strong stakeholder engagement-developers and payors alike can unlock significant value. Careful orchestration of these elements will define the next chapter in biosimilar mAb evolution, ensuring broader patient access and delivering healthcare systems the savings they seek.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Molecule Class
    • Anti Cd20
    • Anti Her2
    • Anti Vascular Endothelial Growth Factor
      • Aflibercept
      • Bevacizumab
      • Ranibizumab
    • Colony Stimulating Factors
      • Filgrastim
      • Pegfilgrastim
    • Tnf Inhibitors
      • Adalimumab
      • Etanercept
      • Infliximab
  • Indication
    • Inflammatory Bowel Disease
      • Crohn Disease
      • Ulcerative Colitis
    • Neutropenia
    • Oncology
      • Breast Cancer
      • Colorectal Cancer
      • Lung Cancer
    • Psoriasis
      • Plaque Psoriasis
      • Psoriatic Arthritis
    • Rheumatoid Arthritis
      • Adult Rheumatoid Arthritis
      • Juvenile Idiopathic Arthritis
  • Dosage Form
    • Liquid Solution
    • Prefilled Pen
    • Prefilled Syringe
    • Vial
      • Liquid Vial
      • Lyophilized Powder
  • Distribution Channel
    • Offline
    • Online
  • End User
    • Hospital Pharmacy
      • Private Hospital
      • Public Hospital
    • Retail Pharmacy
      • Chain Pharmacy
      • Independent Pharmacy
    • Specialty Clinics
      • Dermatology Clinic
      • Oncology Center
      • Rheumatology Clinic
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Sandoz International GmbH
  • Pfizer Inc.
  • Amgen Inc.
  • Samsung Bioepis Co., Ltd.
  • Celltrion, Inc.
  • Biocon Ltd.
  • Coherus BioSciences, Inc.
  • Merck KGaA
  • Fresenius Kabi AG
  • Viatris Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Biosimilar Monoclonal Antibodies Market, by Molecule Class
8.1. Introduction
8.2. Anti Cd20
8.3. Anti Her2
8.4. Anti Vascular Endothelial Growth Factor
8.4.1. Aflibercept
8.4.2. Bevacizumab
8.4.3. Ranibizumab
8.5. Colony Stimulating Factors
8.5.1. Filgrastim
8.5.2. Pegfilgrastim
8.6. Tnf Inhibitors
8.6.1. Adalimumab
8.6.2. Etanercept
8.6.3. Infliximab
9. Biosimilar Monoclonal Antibodies Market, by Indication
9.1. Introduction
9.2. Inflammatory Bowel Disease
9.2.1. Crohn Disease
9.2.2. Ulcerative Colitis
9.3. Neutropenia
9.4. Oncology
9.4.1. Breast Cancer
9.4.2. Colorectal Cancer
9.4.3. Lung Cancer
9.5. Psoriasis
9.5.1. Plaque Psoriasis
9.5.2. Psoriatic Arthritis
9.6. Rheumatoid Arthritis
9.6.1. Adult Rheumatoid Arthritis
9.6.2. Juvenile Idiopathic Arthritis
10. Biosimilar Monoclonal Antibodies Market, by Dosage Form
10.1. Introduction
10.2. Liquid Solution
10.3. Prefilled Pen
10.4. Prefilled Syringe
10.5. Vial
10.5.1. Liquid Vial
10.5.2. Lyophilized Powder
11. Biosimilar Monoclonal Antibodies Market, by Distribution Channel
11.1. Introduction
11.2. Offline
11.3. Online
12. Biosimilar Monoclonal Antibodies Market, by End User
12.1. Introduction
12.2. Hospital Pharmacy
12.2.1. Private Hospital
12.2.2. Public Hospital
12.3. Retail Pharmacy
12.3.1. Chain Pharmacy
12.3.2. Independent Pharmacy
12.4. Specialty Clinics
12.4.1. Dermatology Clinic
12.4.2. Oncology Center
12.4.3. Rheumatology Clinic
13. Americas Biosimilar Monoclonal Antibodies Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Biosimilar Monoclonal Antibodies Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Biosimilar Monoclonal Antibodies Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Sandoz International GmbH
16.3.2. Pfizer Inc.
16.3.3. Amgen Inc.
16.3.4. Samsung Bioepis Co., Ltd.
16.3.5. Celltrion, Inc.
16.3.6. Biocon Ltd.
16.3.7. Coherus BioSciences, Inc.
16.3.8. Merck KGaA
16.3.9. Fresenius Kabi AG
16.3.10. Viatris Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET MULTI-CURRENCY
FIGURE 2. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET MULTI-LANGUAGE
FIGURE 3. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTI CD20, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTI HER2, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COLONY STIMULATING FACTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY FILGRASTIM, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PEGFILGRASTIM, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ADALIMUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ETANERCEPT, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLIXIMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CROHN DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY NEUTROPENIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PLAQUE PSORIASIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ADULT RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY JUVENILE IDIOPATHIC ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY LIQUID SOLUTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PREFILLED PEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY VIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY LIQUID VIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DERMATOLOGY CLINIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONCOLOGY CENTER, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RHEUMATOLOGY CLINIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 101. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2030 (USD MILLION)
TABLE 102. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR, 2018-2030 (USD MILLION)
TABLE 103. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 104. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 105. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 106. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 107. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 108. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 109. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 110. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 111. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 112. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 113. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 114. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 115. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 116. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 117. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2030 (USD MILLION)
TABLE 118. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR, 2018-2030 (USD MILLION)
TABLE 119. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 120. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 121. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 122. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 123. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 124. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 125. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 126. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 127. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 128. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 129. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 130. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 131. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 132. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 133. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2030 (USD MILLION)
TABLE 134. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR, 2018-2030 (USD MILLION)
TABLE 135. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 136. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 137. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 138. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 139. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 140. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 141. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 142. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 143. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 144. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 145. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 146. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 147. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 148. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 149. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2030 (USD MILLION)
TABLE 150. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR, 2018-2030 (USD MILLION)
TABLE 151. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 152. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 153. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 154. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 155. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 156. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 157. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 158. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 159. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 160. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 161. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 162. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 163. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 164. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2030 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR, 2018-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 182. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR, 2018-2030 (USD MILLION)
TABLE 184. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 186. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 188. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 190. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 192. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 194. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 196. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 198. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2030 (USD MILLION)
TABLE 199. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR, 2018-2030 (USD MILLION)
TABLE 200. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 201. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 202. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 203. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 204. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 205. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 206. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 207. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 208. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 209. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 210. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 212. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 213. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 214. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2030 (USD MILLION)
TABLE 215. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR, 2018-2030 (USD MILLION)
TABLE 216. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 217. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 218. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 219. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 220. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 221. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 222. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 223. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 224. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 225. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 226. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 227. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 228. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 229. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 230. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2030 (USD MILLION)
TABLE 231. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR, 2018-2030 (USD MILLION)
TABLE 232. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 233. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 234. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 235. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 236. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 237. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 238. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 239. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 240. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 241. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 242. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 243. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 244. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 245. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 246. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2030 (USD MILLION)
TABLE 247. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR, 2018-2030 (USD MILLION)
TABLE 248. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 249. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 250. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 251. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 252. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 253. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 254. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 255. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 256. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 257. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 258. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 259. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 260. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 261. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 262. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2030 (USD MILLION)
TABLE 263. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR, 2018-2030 (USD MILLION)
TABLE 264. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 265. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 266. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 267. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 268. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 269. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 270. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 271. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 272. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 273. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 274. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 275. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 276. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 277. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 278. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2030 (USD MILLION)
TABLE 279. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR, 2018-2030 (USD MILLION)
TABLE 280. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 281. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 285. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 288. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 289. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 290. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 291. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARK

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Biosimilar Monoclonal Antibodies market report include:
  • Sandoz International GmbH
  • Pfizer Inc.
  • Amgen Inc.
  • Samsung Bioepis Co., Ltd.
  • Celltrion, Inc.
  • Biocon Ltd.
  • Coherus BioSciences, Inc.
  • Merck KGaA
  • Fresenius Kabi AG
  • Viatris Inc.

Table Information

Report AttributeDetails
No. of Pages197
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 11.73 Billion
Forecasted Market Value ( USD ) by 2030 $ 33.22 Billion
Compound Annual Growth Rate23.2%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Biosimilars Market by Product Type, Therapeutic Area, Administration Route, End User - Global Forecast to 2030 - Product Image

Biosimilars Market by Product Type, Therapeutic Area, Administration Route, End User - Global Forecast to 2030

  • Report
  • 187 Pages
  • Global
From
Biosimilar Monoclonal Antibody - Global Strategic Business Report - Product Image

Biosimilar Monoclonal Antibody - Global Strategic Business Report

  • Report
  • 235 Pages
  • Global
From
Biosimilars Market - Products, Applications and Regulations - Product Image

Biosimilars Market - Products, Applications and Regulations

  • Report
  • 227 Pages
  • Global
From
Biosimilars - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Biosimilars - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 100 Pages
  • Global
From
Biosimilar Monoclonal Antibodies Market Report 2025 - Product Image

Biosimilar Monoclonal Antibodies Market Report 2025

  • Report
  • 250 Pages
  • Global
From

About the Monoclonal Antibodies Market

Biosimilar Monoclonal Antibodies (mAbs) are biotechnological products that are similar to existing monoclonal antibodies (mAbs) that are already approved for use in humans. Biosimilar mAbs are developed using recombinant DNA technology and are designed to have the same structure and function as the original mAbs. Biosimilar mAbs are used to treat a variety of diseases, including cancer, autoimmune diseases, and infectious diseases. They are also used in research and development of new treatments. The biosimilar mAbs market is growing rapidly due to the increasing demand for mAbs in the treatment of various diseases. The market is expected to continue to grow as more mAbs are developed and approved for use in humans. Additionally, the increasing demand for mAbs in research and development is expected to drive the growth of the market. Some companies in the biosimilar mAbs market include Amgen, Biogen, Merck, Pfizer, and Novartis. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.
OSZAR »